Mar. 11, 2012
Sihuan Pharmaceutical announced on March 12, 2012 that its application to begin clinical trials of a new treatment for hypertension was accepted by the SFDA. The company is developing Tylerdipine Hydrochloride, a calcium channel blocker, in its own facilities. Results from pre-clinical studies have shown that Tylerdipine Hydrochloride is a superior agent in blocking L-type and T-type calcium channels. The Company believes Tylerdipine Hydrochloride can effectively curb hypertension in clinical practice while offering protection to important organs such as the heart and kidneys.